BTIG raised the firm’s price target on Akebia (AKBA) to $10 from $5 and keeps a Buy rating on the shares. The firm cites the company’s Vafseo launch earlier this month in chronic kidney ...

The FDA, which turned away Akebia's initial application last March 2022, has a target action of Wednesday on the company's resubmission, which included Explore Our Brands WSJ ...

Analyst Ed Arce of H.C. Wainwright maintained a Buy rating on Akebia Therapeutics (AKBA – Research Report), retaining the price target of $7.50. Discover outperforming stocks and invest smarter ...

CAMBRIDGE, Mass., Jan. 13, 2025 /PRNewswire/ -- Akebia Therapeutics ®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease ...